Dr Lal PathLabs is buying a 70% stake in SN Genelab for ₹168 crore, plus ₹31.5 crore in contingent payouts. SN Genelab recorded FY26 revenue of ₹58 crore and a 26% EBITDA margin. https://www.theceo.in/newsletter #DrLalPathLabs #SNGenelab #MAndA